QS Investors’s Catalyst Pharmaceutical CPRX Stock Holding History

QS Investors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-86,400	Closed	-$399K	–	1122
2021 Q1	$399K	Sell	86,400 -1,882	-2%	-$7.48K	﹤0.01%	883
2020 Q4	$295K	Hold	88,282	–	–	﹤0.01%	999
2020 Q3	$263K	Sell	88,282 -361,900	-80%	-$1.42M	﹤0.01%	966
2020 Q2	$2.08M	Hold	450,182	–	–	0.03%	471
2020 Q1	$1.73M	Hold	450,182	–	–	0.03%	473
2019 Q4	$1.7M	Buy	450,182 +449,000	+37,986%	+$2.1M	0.02%	636
2019 Q3	$7K	Hold	1,182	–	–	﹤0.01%	1574
2019 Q2	$5K	Hold	1,182	–	–	﹤0.01%	1594
2019 Q1	$7K	Hold	1,182	–	–	﹤0.01%	1572
2018 Q4	$3K	Hold	1,182	–	–	﹤0.01%	1615
2018 Q3	$4K	Hold	1,182	–	–	﹤0.01%	1616
2018 Q2	$4K	Buy	1,182 +89	+8%	+$270	﹤0.01%	1633
2018 Q1	$3K	Hold	1,093	–	–	﹤0.01%	1647
2017 Q4	$4K	Buy	+1,093	New	+$3.61K	﹤0.01%	1613

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QS Investors's CPRX Position: Q2 2021 in Review

QS Investors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2021, closing a stake of 86,400 shares — an estimated $399K sold.

QS Investors first reported a position in CPRX in Q4 2017 and held it in 14 quarters. The position peaked at $2.08M in Q2 2020. 139 funds tracked by Wall St. Rank hold CPRX as of Q2 2021.

QS Investors reported no remaining Catalyst Pharmaceutical position as of Q2 2021 after selling out during the quarter.
QS Investors sold 86,400 Catalyst Pharmaceutical shares in Q2 2021, an estimated $399K.
QS Investors first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 14 quarters.
QS Investors's Catalyst Pharmaceutical position peaked at $2.08M in Q2 2020.
139 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.